The effect of parthenium Tanacetum on epilepsy

Phase 2

Recruiting

• Conditions: Drug-resistant epilepsy.; Episodic and paroxysmal disorders(G40-G47); Epilepsy

• Registration Number: IRCT20190406043175N10
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

children aged 2-18 years who refer to the clinic or neurology department of Qaim Hospital and treatment-resistant epilepsy clinic
Epilepsy (based on clinical findings and brain scan) is defined in such a way that despite receiving medication, their seizures are not controlled and are resistant to treatment.

Exclusion Criteria

Presence of underlying metabolic disorder
Existence of systemic diseases
Allergy to chamomile
Respiratory sensitivity leading to mouth breathing
Non-continuous use of the essential oil used in the research
Intensification of convulsions for any reason that requires a change in medication

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of epilepsy attack. Timepoint: Early intervention, four weeks after the intervention, eight weeks after intervention. Method of measurement: Questionnaire.;Diversity of epilepsy attack. Timepoint: Early intervention, four weeks after the intervention, eight weeks after intervention. Method of measurement: Questionnaire.;Duration of epilepsy attack. Timepoint: Early intervention, four weeks after the intervention, eight weeks after intervention. Method of measurement: Questionnaire.;Time of epileptic attacks. Timepoint: Early intervention, four weeks after the intervention, eight weeks after intervention. Method of measurement: Questionnaire.